title: Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.
abstract: OBJECTIVE
  As one of the only two isoforms of the eukaryotic initiation factor (EIF)5A family, EIF5A2 plays an important role in tumour progression and prognosis evaluation. The aim of this study was to investigate EIF5A2 expression in International Federation of Gynecology and Obstetrics (FIGO) stage I-II cervical cancer and to evaluate its clinical significance.
  
  
  RESULTS
  The mRNA and protein expression levels of EIF5A2 were analysed in 20 tissue samples of FIGO stage I-II cervical cancer and paired surrounding non-tumour cervical tissues by real-time polymerase chain reaction and western blot analysis. Immunohistochemistry was performed to examine EIF5A2 protein expression in paraffin-embedded tissues from 314 patients with cervical cancer. The mRNA and protein expression levels of EIF5A2 were significantly elevated in tumour tissues. The increased EIF5A2 expression was correlated with higher FIGO stage (P < 0.001), deep cervical stromal invasion (P = 0.026), lymphovascular space involvement (P = 0.002), pelvic lymph node metastasis (P < 0.001) and postoperative recurrence (P < 0.001) in patients with cervical cancer. Patients with tumours showing high EIF5A2 expression had a poorer survival time than those with normal EIF5A2 expression, especially the patients with negative pelvic lymph nodes and FIGO stage II. In addition, multivariate Cox analysis showed that high EIF5A2 expression was an independent prognostic factor for overall survival [hazard ratio 1.949; 95% confidence interval (CI) 1.116-3.404; P = 0.019] and disease-free survival (hazard ratio 1.980; 95% CI 1.189-3.297; P = 0.009).
  
  
  CONCLUSIONS
  EIF5A2 overexpression may contribute to cancer progression and poor prognosis. Therefore, EIF5A2 could be a novel potential prognostic marker for FIGO stage I-II cervical cancer.
authors.affiliation: Department of Gynaecological Radiotherapy, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Yang
authors.affiliation: Department of Gynaecology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
authors.forename: De-Ying
authors.initials: DY
authors.lastname: Wang
authors.affiliation: Department of Gynaecology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Bai-Rong
authors.initials: BR
authors.lastname: Xia
authors.affiliation: Department of Gynaecology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Yun-Duo
authors.initials: YD
authors.lastname: Liu
authors.affiliation: Department of Pathology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Qin
authors.affiliation: Department of Pathology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Ning
authors.affiliation: Department of Gynaecological Radiotherapy, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Gen-Ying
authors.initials: GY
authors.lastname: Li
authors.affiliation: Department of Gynaecological Radiotherapy, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Li-Xiao
authors.initials: LX
authors.lastname: Hao
authors.affiliation: Department of Breast Surgery, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Min
authors.initials: M
authors.lastname: Xiao
authors.affiliation: Department of Gynaecology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.
authors.forename: Yun-Yan
authors.initials: YY
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D010448:Peptide Initiation Factors / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D016601:RNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D060888:Real-Time Polymerase Chain Reaction; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D000097574:Eukaryotic Translation Initiation Factor 5A
chemical_list: D014408:Biomarkers, Tumor; D010448:Peptide Initiation Factors; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D000097574:Eukaryotic Translation Initiation Factor 5A
keywords: cervical cancer; eukaryotic initiation factor 5A2; prognosis; progression